Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Iovance Biotherapeutics (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ESMO 2021 | DESTINY-Lung01: cohort expansion results

Sanjay Popat, BSc, MBBS, FRCP, PhD, The Royal Marsden NHS Foundation Trust, London, UK, discusses the cohort expansion results from the Phase Ib DESTINY-Lung01 trial (NCT03505710), presented by Dr Bob Li at ESMO 2021, which looked at trastuzumab deruxtecan for patients with HER2 mutant non-small cell lung cancer (NSCLC). Overall response rate was 55%, median progression-free survival was 8.2 months, and the median overall survival was 17.8 months, with nearly all patients having tumour shrinkage. Prof. Popat highlights how encouraging these trial results are for patients with NSCLC. This interview took place at the European Society for Medical Oncology (ESMO) 2021 congress.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.